A detailed history of Endurance Wealth Management, Inc. transactions in Exact Sciences Corp stock. As of the latest transaction made, Endurance Wealth Management, Inc. holds 5,075 shares of EXAS stock, worth $291,711. This represents 0.07% of its overall portfolio holdings.

Number of Shares
5,075
Previous 5,825 12.88%
Holding current value
$291,711
Previous $395,000 20.76%
% of portfolio
0.07%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 09, 2023

SELL
$62.68 - $95.05 $47,010 - $71,287
-750 Reduced 12.88%
5,075 $477,000
Q1 2023

May 02, 2023

SELL
$47.19 - $70.77 $44,830 - $67,231
-950 Reduced 14.02%
5,825 $395,000
Q4 2022

Feb 01, 2023

SELL
$30.35 - $53.15 $4,249 - $7,441
-140 Reduced 2.02%
6,775 $336,000
Q3 2022

Oct 21, 2022

SELL
$31.97 - $49.37 $6,394 - $9,874
-200 Reduced 2.81%
6,915 $224,000
Q2 2022

Jul 20, 2022

SELL
$35.61 - $76.23 $30,268 - $64,795
-850 Reduced 10.67%
7,115 $281,000
Q1 2022

Apr 20, 2022

BUY
$57.56 - $82.54 $54,682 - $78,413
950 Added 13.54%
7,965 $557,000
Q4 2021

Jan 19, 2022

BUY
$72.5 - $100.68 $182,337 - $253,210
2,515 Added 55.89%
7,015 $546,000
Q3 2021

Oct 28, 2021

BUY
$90.24 - $124.05 $139,872 - $192,277
1,550 Added 52.54%
4,500 $429,000
Q2 2021

Aug 04, 2021

BUY
$93.66 - $139.27 $74,928 - $111,416
800 Added 37.21%
2,950 $366,000
Q1 2021

May 05, 2021

BUY
$116.57 - $155.01 $40,799 - $54,253
350 Added 19.44%
2,150 $284,000
Q3 2020

Oct 27, 2020

BUY
$72.92 - $102.01 $102,088 - $142,814
1,400 Added 350.0%
1,800 $184,000
Q2 2020

Jul 14, 2020

SELL
$55.75 - $92.75 $33,450 - $55,650
-600 Reduced 60.0%
400 $35,000
Q1 2020

May 11, 2020

BUY
$37.9 - $104.44 $37,900 - $104,440
1,000 New
1,000 $58,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Endurance Wealth Management, Inc. Portfolio

Follow Endurance Wealth Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurance Wealth Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Endurance Wealth Management, Inc. with notifications on news.